FDA says Avastin should no longer be used for breast cancer, Genentech plans appeal
This article was originally published in Scrip
Genentech's top-selling anticancer drug Avastin (bevacizumab) should no longer be marketed for the treatment of metastatic breast cancer, the FDA has said in rare and controversial decision to withdraw its accelerated marketing approval of a drug, which follows the recommendation of its advisory committee.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.